Screening for neuroblastoma in late infancy by use of EIA (enzyme-linked immunoassay) method: 115,000 screened infants in Austria

European Journal of Cancer Part A

Volumn 32, Issue 13, 1996, Pages 2298-2305

  Kerbl, R ^a   Urban, C E ^a   Ambros, P F ^b   Lackner, H ^a   Ladenstein, R ^b   Spuller, E ^c   Mutz, I ^d   Ambros, I ^b   Amann, G ^e   Gadner, H ^b   Parker, L ^f  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

^d Department of Paediatrics ^*  (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

^f ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Biological features; EIA; High performance liquid chromatography; N myc; Neuroblastoma screening; Urine catecholamines

Indexed keywords

ARTICLE; AUSTRIA; CANCER SCREENING; CANCER STAGING; CATECHOLAMINE URINE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PRIORITY JOURNAL;

AUSTRIA; CATECHOLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MASS SCREENING; NEUROBLASTOMA; PATIENT COMPLIANCE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0030461990     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00361-9     Document Type: Article

References (40)

1. 1. Sawada T, Sugimoto T, Tanaka T, et al. Number and cure rate of neuroblastoma cases detected by the mass screening programme in Japan: future aspects. Med Pediatr Oncol 1987, 15, 14-17.
2. 2. Sawada T, Matsumura T, Kawakatsu H, et al. Long-term effects of mass screening for neuroblastoma in infancy. Am J Pediatr Hematol Oncol 1991, 13, 3-7.
3. 3. Hanawa Y, Sawada T, Tsunoda A. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol 1990, 18, 472-475.
4. 4. Nishi M, Miyake H, Takeda T, et al. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987, 60, 433-436.
5. 5. Kerbl R, Starz I, Urban C. Neuroblastoma screening for Austria by use of EIA-methods. Second International Symposium on Neuroblastoma Screening, Minneapolis, May 22-24, 1991.
6. 6. Ishimoto K, Kiyokawa N, Fujita H, et al. Problems of mass screening for neuroblastoma: analysis of false-negative cases. J Pediatr Surg 1990, 25, 398-401.
7. 7. Kaneko Y, Kanda N, Maseki N, et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. J Clin Oncol 1990, 8, 2005-2013.
8. 8. Parker L, Craft AW. Neuroblastoma screening: more questions than answers? [editorial]. Eur J Cancer 1991, 27, 682-683.
9. 9. Nakagawara A, Zaizen Y, Ikeda K, et al. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas. Cancer 1991, 68, 2037-2044.
10. 10. Murphy SB, Cohn SL, Craft AW, et al. Do children benefit from mass screening for neuroblastoma? Lancet 1991, 337, 344-346.
11. 11. Cole M, Parker L, Craft AW. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol 1992, 20, 84-85.
12. 12. Yokomori H, Hori T, Tsuchida Y, Kuroda M, Yoshioka M. A new urinary mass screening system for neuroblastoma in infancy by use of monoclonal antibodies against VMA and HVA. J Pediatr Surg 1989, 24, 391-394.
13. 13. Ladenstein R, Urban C, Gadner H, et al. First experience with prognostic factors in unselected neuroblastoma patients. The Austrian Neuroblastoma 87 Study. Eur J Cancer 1995, 31A, 637-641.
14. 14. Beck D, De Bernardi B, Michon J, Ambros PF. Phase II clinical trial of surgery as the only treatment for INSS stage 2 neuroblastoma (94.01 trial and study of the Localized Neuroblastoma European Study Group; SIOP 95.01 study). Med Pediat Oncol 1995, 25, 278.
15. 15. Kushner BH, LaQuaglia MP, Ambros PF, et al. Survival from locally invasive or metastatic neuroblastoma without cytotoxic therapy. Proc Am Soc Clin Oncol 1993, 12, 413.
16. 16. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Cancer 1971, 27, 374-378.
17. 17. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993, 11, 1466-1477.
18. 18. Shimada H, Chatten J, Newton WA, et al. Histopathologic prognostic factors in neuroblastoma tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastoma. J Natl Cancer Inst 1984, 73, 405-416.
19. 19. Joshi VV, Cantor AB, Broduer GM, et al. Correlation between morphologic and other prognostic markers of neuroblastoma. Cancer 1993, 71, 3173-3181.
20. 20. Schweizer D, Ambros PF. Chromosome banding. Stain combinations for specific regions. Chromosome Analysis Protocols 1994, 29, 97-112.
21. 21. Strehl S, Ambros PF. Fluorescence in situ hybridisation combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma. Cytogenet Cell Genet 1993, 63, 24-28.
22. 22. Parker L, Craft AW, Dale G, et al. Screening for neuroblastoma in the north of England. Br Med J 1992, 305, 1260-1263.
23. 23. Woods WG, Tuchman M, Bernstein ML, et al. Screening for neuroblastoma in North America. 2-year-results from the Quebec project. Am J Pediatr Hematol Oncol 1992, 14, 312-319.
24. 24. Schilling FH, Erttmann R, Ambros PF, et al. Screening for neuroblastoma [letter]. Lancet 1994, 344, 1157-1158.
25. 25. Frappaz D, Mathieu P, Chauvin F, Brunat Mentigny M, Esteve J, Philip T. Results of screening for neuroblastoma (NB) in Rhone district. Fourth International Symposium on Neuroblastoma Screening, Stuttgart/Germany, November 9-11, 1995.
26. 26. Baillot A, Biedler H, Berthold F, Sander J. Screening for neuroblastoma in Lower-Saxony and Northrhine-Westphalia: methods and preliminary results of 272,000 infants tested. Fourth International Symposium on Neuroblastoma Screening, Stuttgart/Germany, November 9-11, 1995.
27. 27. Gleisbach H, Huber E, Fauler G, Kerbl R, Urban C, Leis HJ. Neuroblastoma screening: labeling of catecholamines for stable isotope dilution gas chromatography-mass spectrometry. Nutrition, in press.
28. 28. Sawada T, Numata K, Otabe N, et al. Neuroblastoma screening in Japan: past-present-future. Fourth International Symposium on Neuroblastoma Screening, Stuttgart/Germany, November 9-11, 1995.
29. 29. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992, 52, 1364-1368.
30. 30. Hayashi Y, Kanada R, Yamamoto K. Biology of neuroblastomas in Japan found by screening. Am J Pediatr Hematol Oncol 1992, 14, 342-347.
31. 31. Ariyoshi N. Different characteristics of neuroblastomas in cases found by mass screening and non-screening: evaluation of mass screening for neuroblastoma in Kitakyushu City. Sangyo Ika Daigaku Zasshi 1993, 15, 251-266.
32. 32. Woods WG, Lemieux B, Tuchman M. Neuroblastoma represents distinct clinical-biologic entities: a review from the Quebec Neuroblastoma Screening Project. Pediatrics 1992, 89, 114-118.
33. 33. Tuchman M, Lemieux B, Robison LL, et al. Screening for neuroblastoma (NB) increases the overall incidence of the disease without reducing the incidence of advanced stage NB. Fourth International Symposium on Neuroblastoma Screening, Stuttgart/ Germany, November 9-11, 1995.
34. 34. Stiller CA. Trends in neuroblastoma in Great Britain: incidence and mortality 1971-1990. Eur J Cancer 1993, 29A, 1008-1012.
35. 35. Kaatsch P, Haaf G, Michaelis J. Childhood malignancies in Germany - methods and results of a nationwide registry. Eur J Cancer 1995, 31A, 993-999.
36. 36. Hachitanda Y, Ishimoto K, Jun-ichi H, Shimada H. One hundred neuroblastomas detected through a mass screening system in Japan. Cancer 1994, 74, 3223-3226.
37. 37. Kusafuka T, Nagahara N, Oue T, et al. Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastoma detected through mass screening. Cancer 1995, 76, 695-699.
38. 38. Carlsen NL. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening. Am J Pediatr Hematol Oncol 1992, 14, 103-110.
39. 39. Schilling FH, Berthold F, Erttmann R, Sander J, Treuner J. An epidemiological study to evaluate neuroblastoma screening at 12 months of age in Germany. Fourth International Symposium on Neuroblastoma Screening, Stuttgart/Germany, November 9-11, 1995.
40. 40. Esteve J, Parker L, Roy P, et al. Is neuroblastoma screening needed and feasible? Br J Cancer 1995, 71, 1125-1131.